{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:43Z","timestamp":1787010163733,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,31]]},"abstract":"<jats:p>Cerebral amyloid angiopathy (CAA), which is prevalent among older adults, constitutes a major cause of brain hemorrhage, dementia, and cognitive decline. Currently, no effective treatments for alleviating the disease of CAA exist. Hence, the discovery of novel drug targets for CAA is of utmost significance. Cis-expression quantitative trait locus (cis-eQTL) of druggable genes from eQTLGen Consortium and genome-wide association study of CAA from FinnGen database were used to screen for drug-usable genes causally associated with CAA. Robustness was assessed using colocalization analysis and heterogeneity in dependent instruments (HEIDI) tests. Significant findings were further validated using summary-data-based Mendelian randomization (SMR) with blood and arterial tissue eQTL data from eQTLGen and GTEx. Potential drugs targeting prioritized genes were screened using the DSigDB database, and binding interactions were evaluated via molecular docking. Mendelian randomization analysis identified 10 druggable genes significantly associated with CAA risk (false discovery rate\u2005&lt;\u20050.1). Colocalization analysis revealed strong evidence (PPH4\u2005&gt;\u20050.75) that dipeptidyl peptidase 9 (DPP9) and CAA share a causal genetic variant. DPP9 is a member of the dipeptidyl peptidase IV family and participates in cellular energy metabolism. SMR with HEIDI test confirmed the causal relationship between genetically predicted DPP9 expression and increased CAA risk in both blood (P_SMR\u2005&lt;\u20050.05, P_HEIDI&gt;0.05) and arterial tissues (P_SMR\u2005&lt;\u20050.05, P_HEIDI&gt;0.05). Drug screening identified sitagliptin and zoledronic acid as potential DPP9-targeting compounds. Molecular docking demonstrated a highly favorable binding interaction between sitagliptin and DPP9 (binding energy\u2005=\u2005\u22129.0 kcal\/mol). This study provides genetic evidence identifying DPP9 as a potential drug target for CAA. The antidiabetic drug sitagliptin, predicted to bind DPP9 with high affinity, represents a promising candidate for therapeutic repurposing in CAA.<\/jats:p>","DOI":"10.1097\/md.0000000000045643","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:01:48Z","timestamp":1763571708000},"page":"e45643","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Identifying potential drug targets for cerebral amyloid angiopathy: A Mendelian randomization study based on the druggable genes"],"prefix":"10.1097","volume":"104","author":[{"given":"Jiuchang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China"},{"name":"Department of Neurology, Jining No. 1 People\u2019s Hospital, Jining, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anmu","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1650-3419","authenticated-orcid":false,"given":"Zhongrui","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jining No. 1 People\u2019s Hospital, Jining, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260520","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways.","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"R2-20260520","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1002\/alz.13826","article-title":"Cerebral amyloid angiopathy and the immune system.","volume":"20","author":"Munsterman","year":"2024","journal-title":"Alzheimers Dement"},{"key":"R3-20260520","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5853\/jos.2023.01942.e1","article-title":"Cerebral amyloid angiopathy: an undeniable small vessel disease [published correction appears in J Stroke. 2024 May;26(2):347].","volume":"26","author":"Wang","year":"2024","journal-title":"J Stroke"},{"key":"R4-20260520","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1186\/s12967-023-04474-z","article-title":"Identification of potential drug targets for rheumatoid arthritis from genetic insights: a Mendelian randomization study.","volume":"21","author":"Cao","year":"2023","journal-title":"J Transl Med"},{"key":"R5-20260520","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","article-title":"Genetic drug target validation using Mendelian randomisation.","volume":"11","author":"Schmidt","year":"2020","journal-title":"Nat Commun"},{"key":"R6-20260520","doi-asserted-by":"crossref","first-page":"eaag1166","DOI":"10.1126\/scitranslmed.aag1166","article-title":"The druggable genome and support for target identification and validation in drug development.","volume":"9","author":"Finan","year":"2017","journal-title":"Sci Transl Med"},{"key":"R7-20260520","doi-asserted-by":"crossref","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.3","article-title":"Guidelines for performing Mendelian randomization investigations: update for summer 2023.","volume":"4","author":"Burgess","year":"2023","journal-title":"Wellcome Open Res"},{"key":"R8-20260520","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12931-024-02848-5","article-title":"Identifying potential drug targets for idiopathic pulmonary fibrosis: a mendelian randomization study based on the druggable genes.","volume":"25","author":"Liu","year":"2024","journal-title":"Respir Res"},{"key":"R9-20260520","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","article-title":"Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression.","volume":"53","author":"V\u00f5sa","year":"2021","journal-title":"Nat Genet"},{"key":"R10-20260520","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/sim.6522","article-title":"Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome.","volume":"34","author":"Greco M","year":"2015","journal-title":"Stat Med"},{"key":"R11-20260520","doi-asserted-by":"crossref","first-page":"e1004383","DOI":"10.1371\/journal.pgen.1004383","article-title":"Bayesian test for colocalisation between pairs of genetic association studies using summary statistics.","volume":"10","author":"Giambartolomei","year":"2014","journal-title":"PLoS Genet"},{"key":"R12-20260520","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ng.3538","article-title":"Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets.","volume":"48","author":"Zhu","year":"2016","journal-title":"Nat Genet"},{"key":"R13-20260520","doi-asserted-by":"crossref","first-page":"6680637","DOI":"10.1155\/2021\/6680637","article-title":"Mechanism of modified Danggui Sini decoction for knee osteoarthritis based on network pharmacology and molecular docking.","volume":"2021","author":"Feng","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"key":"R14-20260520","doi-asserted-by":"crossref","first-page":"27211","DOI":"10.1074\/jbc.M109.041871","article-title":"The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides.","volume":"284","author":"Geiss-Friedlander","year":"2009","journal-title":"J Biol Chem"},{"key":"R15-20260520","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1111\/febs.13371","article-title":"Identification of novel dipeptidyl peptidase 9 substrates by two-dimensional differential in-gel electrophoresis.","volume":"282","author":"Zhang","year":"2015","journal-title":"FEBS J"},{"key":"R16-20260520","doi-asserted-by":"crossref","first-page":"12348","DOI":"10.1038\/srep12348","article-title":"Inhibition of dipeptidyl peptidase 8\/9 impairs preadipocyte differentiation.","volume":"5","author":"Han","year":"2015","journal-title":"Sci Rep"},{"key":"R17-20260520","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.3748\/wjg.v19.i19.2883","article-title":"Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.","volume":"19","author":"Chowdhury","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R18-20260520","doi-asserted-by":"crossref","first-page":"1002871","DOI":"10.3389\/fphar.2022.1002871","article-title":"New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors.","volume":"13","author":"Cui","year":"2022","journal-title":"Front Pharmacol"},{"key":"R19-20260520","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00395-013-0350-4","article-title":"Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis.","volume":"108","author":"Matheeussen","year":"2013","journal-title":"Basic Res Cardiol"},{"key":"R20-20260520","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1515\/bc.2011.002","article-title":"Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.","volume":"392","author":"Matheeussen","year":"2011","journal-title":"Biol Chem"},{"key":"R21-20260520","doi-asserted-by":"crossref","first-page":"100963","DOI":"10.1016\/j.jbc.2021.100963","article-title":"Dipeptidyl peptidase 4 contributes to Alzheimer\u2019s disease-like defects in a mouse model and is increased in sporadic Alzheimer\u2019s disease brains.","volume":"297","author":"Valverde","year":"2021","journal-title":"J Biol Chem"},{"key":"R22-20260520","doi-asserted-by":"crossref","first-page":"105466","DOI":"10.1016\/j.ebiom.2024.105466","article-title":"The role of neuroinflammation in cerebral amyloid angiopathy.","volume":"110","author":"van den Brink","year":"2024","journal-title":"EBioMedicine"},{"issue":"Suppl 3","key":"R23-20260520","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.3233\/JAD-140027","article-title":"Amyloidosis associated with cerebral amyloid angiopathy: cell signaling pathways elicited in cerebral endothelial cells.","volume":"42","author":"Ghiso","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"R24-20260520","doi-asserted-by":"crossref","first-page":"adv26663","DOI":"10.2340\/actadv.v104.26663","article-title":"Identification of risk factors for gliptin-associated bullous pemphigoid among diabetic patients.","volume":"104","author":"Shalmon","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"R25-20260520","doi-asserted-by":"crossref","first-page":"115755","DOI":"10.1016\/j.biopha.2023.115755","article-title":"SGLT2 and DPP4 inhibitors improve Alzheimer\u2019s disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model.","volume":"168","author":"Sim","year":"2023","journal-title":"Biomed Pharmacother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:04:11Z","timestamp":1779275051000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":25,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045643","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2025-06-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}